IGC Pharma Inc

ASE:IGC

0.45

0.00 (-0.24%)

7:56:03 PM EDT: $0.44 -0.01 (-1.87%)

Market Cap (Intraday)	33.96M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.62 Million
Adjusted EPS	-$0.04

See more estimates

10-Day MA	$0.46
50-Day MA	$0.46
200-Day MA	$0.38

See more pivots

IGC Pharma Inc Stock, ASE:IGC

10224 Falls Road, Potomac, Maryland 20854

United States of America

Phone: +1.301.983.0998

Number of Employees: 67

http://www.igcpharma.com

Description

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.